The national comprehensive cancer network (NCCN) guideline v1.2021 explicitly states that while the frequency of EGFR mutations in LUSC is lower than that in adenocarcinoma, the expert panel recommends that molecular testing should be considered for all patients with LUSC (7). This evidence concerns the gene EGFR and adenocarcinoma.